1
|
Kubasch AS, Peterlin P, Cluzeau T, Götze KS, Sockel K, Teipel R, Jentzsch M, Attalah H, Sebert M, Chermat F, Gloaguen S, Puttrich M, Cross M, Schneider M, Kayser S, Schipp D, Giagounidis A, Tirado-Gonzalez I, Descot A, van de Loosdrecht A, Weigert A, Metzeler KH, Fenaux P, Medyouf H, Platzbecker U, Ades L. Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial. Leukemia 2023; 37:2309-2313. [PMID: 37735558 PMCID: PMC10624604 DOI: 10.1038/s41375-023-02029-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Revised: 08/16/2023] [Accepted: 09/06/2023] [Indexed: 09/23/2023]
Affiliation(s)
- A S Kubasch
- Department of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany
- German MDS Study Group (D-MDS), Leipzig, Germany
- The European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany
| | - P Peterlin
- The European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany
- Service d'hématologie Clinique, CHU de Nantes, Nantes, France
| | - T Cluzeau
- The European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany
- CHU de Nice, Département d'Hématologie Clinique, Nice, France
| | - K S Götze
- German MDS Study Group (D-MDS), Leipzig, Germany
- The European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany
- Department of Medicine III, Klinikum rechts der Isar, TUM, Munich, Germany
| | - K Sockel
- German MDS Study Group (D-MDS), Leipzig, Germany
- Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany
| | - R Teipel
- Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany
| | - M Jentzsch
- Department of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany
| | - H Attalah
- Groupe Francophone des Myélodysplasies, Paris, France
| | - M Sebert
- Groupe Francophone des Myélodysplasies, Paris, France
- Service d'Hématologie Seniors, Hopital Saint Louis, Assistance Publique-Hôpitaux de Paris and Paris Cité University, Paris, France
| | - F Chermat
- Groupe Francophone des Myélodysplasies, Paris, France
| | - S Gloaguen
- German MDS Study Group (D-MDS), Leipzig, Germany
- The European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany
| | | | - M Cross
- Department of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany
| | - M Schneider
- Department of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany
| | - S Kayser
- Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, Germany
- NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - D Schipp
- DS-Statistics, Rosenthal-Bielatal, Germany
| | - A Giagounidis
- German MDS Study Group (D-MDS), Leipzig, Germany
- The European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany
- Department for Oncology, Hematology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany
| | - I Tirado-Gonzalez
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - A Descot
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - A van de Loosdrecht
- The European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany
- Amsterdam UMC, VU University Medical Center, Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands
| | - A Weigert
- Department of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany
| | - K H Metzeler
- Department of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany
| | - P Fenaux
- The European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany
- Groupe Francophone des Myélodysplasies, Paris, France
- Service d'Hématologie Seniors, Hopital Saint Louis, Assistance Publique-Hôpitaux de Paris and Paris Cité University, Paris, France
| | - H Medyouf
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
- Frankfurt Cancer Institute, Frankfurt am Main, Germany
- German Cancer Research Consortium, Frankfurt/Mainz partner site, DKFZ Heidelberg, Heidelberg, Germany
| | - U Platzbecker
- Department of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Leipzig University Hospital, Leipzig, Germany.
- German MDS Study Group (D-MDS), Leipzig, Germany.
- The European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany.
| | - L Ades
- The European Myelodysplastic Neoplasms Cooperative Group (EMSCO), Leipzig, Germany
- Groupe Francophone des Myélodysplasies, Paris, France
- Service d'Hématologie Seniors, Hopital Saint Louis, Assistance Publique-Hôpitaux de Paris and Paris Cité University, Paris, France
| |
Collapse
|
2
|
Tirado-Gonzalez I, Czlonka E, Nevmerzhitskaya A, Soetopo D, Bergonzani E, Mahmoud A, Contreras A, Jeremias I, Platzbecker U, Bourquin JP, Kloz U, Van der Hoeven F, Medyouf H. Correction: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC. Leukemia 2020; 35:294. [PMID: 33262529 DOI: 10.1038/s41375-020-01071-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- I Tirado-Gonzalez
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - E Czlonka
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - A Nevmerzhitskaya
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - D Soetopo
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - E Bergonzani
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - A Mahmoud
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - A Contreras
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - I Jeremias
- Department of Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Münich, German Center for Environmental Health (HMGU), Munich, Germany.,German Cancer Consortium, DKTK Partner Site Munich, Heidelberg, Germany
| | - U Platzbecker
- University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.,German Cancer Consortium, DKTK Partner Site Dresden, Heidelberg, Germany
| | - J P Bourquin
- Division of Pediatric Oncology, University Children's Hospital, Zurich, Switzerland
| | - U Kloz
- Division of Pediatric Oncology, University Children's Hospital, Zurich, Switzerland
| | - F Van der Hoeven
- Transgenic Service, German Cancer Research Center, Heidelberg, Germany
| | - H Medyouf
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany. .,German Cancer Consortium, DKTK Partner Site Frankfurt/Mainz, Heidelberg, Germany. .,Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty, University of Heidelberg, Mannheim, Germany.
| |
Collapse
|
3
|
Medyouf H, Tirado-Gonzalez I, Mies A, Nevmerzhitskaya A, Kubasch AS, Platzbecker U. The identification of the AXL/Gas6 signalling axis as a key player of myelodysplastic syndrome (MDS) and the potential of the oral selective AXL inhibitor bemcentinib in the treatment of MDS. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy286.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Tirado-Gonzalez I, Czlonka E, Nevmerzhitskaya A, Soetopo D, Bergonzani E, Mahmoud A, Contreras A, Jeremias I, Platzbecker U, Bourquin JP, Kloz U, Van der Hoeven F, Medyouf H. CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC. Leukemia 2017; 32:1049-1052. [PMID: 29209043 PMCID: PMC7703605 DOI: 10.1038/leu.2017.346] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- I Tirado-Gonzalez
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - E Czlonka
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - A Nevmerzhitskaya
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - D Soetopo
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - E Bergonzani
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - A Mahmoud
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - A Contreras
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - I Jeremias
- Department of Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Münich, German Center for Environmental Health (HMGU), Munich, Germany.,German Cancer Consortium, DKTK Partner Site Munich, Heidelberg, Germany
| | - U Platzbecker
- University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.,German Cancer Consortium, DKTK Partner Site Dresden, Heidelberg, Germany
| | - J P Bourquin
- Division of Pediatric Oncology, University Children's Hospital, Zurich, Switzerland
| | - U Kloz
- Division of Pediatric Oncology, University Children's Hospital, Zurich, Switzerland
| | - F Van der Hoeven
- Transgenic Service, German Cancer Research Center, Heidelberg, Germany
| | - H Medyouf
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.,German Cancer Consortium, DKTK Partner Site Frankfurt/Mainz, Heidelberg, Germany.,Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty, University of Heidelberg, Mannheim, Germany
| |
Collapse
|
5
|
Mossner M, Jann J, Wittig J, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Müdder K, Klein C, Zens B, Platzbecker U, Schönefeldt C, Fabarius A, Blum H, Schulze T, Haferlach C, Trumpp A, Hofmann W, Medyouf H, Nowak D. 65 MYELODYSPLASTIC SYNDROMES ARE CHARACTERIZED BY RECURRENT PATTERNS IN PATIENT-INDIVIDUAL MUTATIONAL HIERARCHIES THAT ARE SUBJECT TO HIGHLY DYNAMIC SUBCLONAL EVOLUTION DURING THERAPY AND DISEASE PROGRESSION. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30066-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Bulycheva E, Rauner M, Medyouf H, Theurl I, Bornhäuser M, Hofbauer LC, Platzbecker U. Myelodysplasia is in the niche: novel concepts and emerging therapies. Leukemia 2014; 29:259-68. [PMID: 25394715 PMCID: PMC4320287 DOI: 10.1038/leu.2014.325] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2014] [Accepted: 09/25/2014] [Indexed: 12/28/2022]
Abstract
Myelodysplastic syndromes (MDSs) represent clonal disorders mainly of the elderly that are characterized by ineffective hematopoiesis and an increased risk of transformation into acute myeloid leukemia. The pathogenesis of MDS is thought to evolve from accumulation and selection of specific genetic or epigenetic events. Emerging evidence indicates that MDS is not solely a hematopoietic disease but rather affects the entire bone marrow microenvironment, including bone metabolism. Many of these cells, in particular mesenchymal stem and progenitor cells (MSPCs) and osteoblasts, express a number of adhesion molecules and secreted factors that regulate blood regeneration throughout life by contributing to hematopoietic stem and progenitor cell (HSPC) maintenance, self-renewal and differentiation. Several endocrine factors, such as erythropoietin, parathyroid hormone and estrogens, as well as deranged iron metabolism modulate these processes. Thus, interactions between MSPC and HSPC contribute to the pathogenesis of MDS and associated pathologies. A detailed understanding of these mechanisms may help to define novel targets for diagnosis and possibly therapy. In this review, we will discuss the scientific rationale of ‘osteohematology' as an emerging research field in MDS and outline clinical implications.
Collapse
Affiliation(s)
- E Bulycheva
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl-Gustav-Carus, Technische Universität, Dresden, Germany
| | - M Rauner
- Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl-Gustav-Carus, Technische Universität, Dresden, Germany
| | - H Medyouf
- Georg-Speyer-Haus, Institut for Tumor Biology and Experimental Therapy, 60596, Frankfurt am Main, Germany
| | - I Theurl
- Department of Internal Medicine VI, Medical University of Innsbruck, Innsbruck, Austria
| | - M Bornhäuser
- 1] Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl-Gustav-Carus, Technische Universität, Dresden, Germany [2] Center for Regenerative Therapies Dresden, Technical University, Dresden, Germany
| | - L C Hofbauer
- 1] Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl-Gustav-Carus, Technische Universität, Dresden, Germany [2] Center for Regenerative Therapies Dresden, Technical University, Dresden, Germany
| | - U Platzbecker
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl-Gustav-Carus, Technische Universität, Dresden, Germany
| |
Collapse
|
7
|
Trumpp A, Medyouf H, Hofmann W, Nowak D. 84: Mesenchymal and MDS stem cells shape an interactive disease unit in the bone marrow. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50084-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Medyouf H, Mossner M, Nolte F, Jann J, Nowak V, Zens B, Müdder K, Oblaender J, Fey S, Fabarius A, Riedl E, Marx A, Roehl H, Mueller N, Metzgeroth G, Hütter G, Hofmann W, Trumpp A, Nowak D. O-013 Mesenchymal stromal cells support significant engraftment of low-risk myelodysplastic syndromes (MDS) in a murine xenograft model. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70035-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Joliot V, Cormier F, Medyouf H, Alcalde H, Ghysdael J. Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis. Oncogene 2006; 25:4573-84. [PMID: 16532027 DOI: 10.1038/sj.onc.1209480] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Signal transducers and activator of transcription 5 (STAT5) A and B are transcriptional regulators that play a central role in cytokine signaling in the hematopoietic lineage and which are frequently activated in a persistent manner in human leukemia/lymphoma, as assessed by their constitutive tyrosine phosphorylation and DNA-binding activity. To study the intrinsic oncogenic properties of persistent STAT5 activation, we generated transgenic mice in which a constitutively activated point mutant of STAT5A, STAT5A(S711F), was expressed at physiological level in their lymphoid compartment. In this model, persistent STAT5 activation is weakly oncogenic, leading to the late emergence of clonal B-cell lymphoma/leukemia at a low incidence. In contrast, STAT5(S711F) was found to cooperate with the loss of function of the p53 tumor suppressor gene to both accelerate disease onset and to skew the large tumor spectrum that normally characterize p53-deficient mice to strongly favor B-cell lymphoma/leukemia. The emergence of STAT5A(S711F)-induced B-cell tumors is associated with the activation of STAT5 tyrosine phosphorylation and DNA-binding activity, indicating that activation of STAT5 oncogenic properties in transgenic STAT5A (TgSTAT5A) (S711F) mice involves the deregulation of STAT5 phosphorylation dynamics.
Collapse
Affiliation(s)
- V Joliot
- Institut Curie, CNRS UMR146, Centre Universitaire, Orsay, France
| | | | | | | | | |
Collapse
|